Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

2.

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ.

Oncologist. 2006 Sep;11(8):857-67. Review.

3.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

4.

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.

Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H.

Cancer Treat Rev. 2008 Oct;34(6):539-57. doi: 10.1016/j.ctrv.2008.03.013. Review.

PMID:
18502589
5.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S.

Oncologist. 2008 Jun;13(6):620-30. doi: 10.1634/theoncologist.2008-0001. Review.

6.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
7.

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.

Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D.

Breast Cancer Res Treat. 2008 May;109(2):231-9. Review.

PMID:
17638068
8.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
9.
10.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

Kabe KL, Kolesar JM.

Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. Review.

PMID:
16522889
11.

The use of HER2 modulation in the adjuvant setting.

Johnson PH, Esteva FJ.

Curr Oncol Rep. 2007 Jan;9(1):9-16. Review.

PMID:
17164042
12.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
13.

Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.

Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.

Clin Ter. 2008 Nov-Dec;159(6):449-52. Review.

PMID:
19169607
14.

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.

Lin A, Rugo HS.

Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Review.

PMID:
17660958
15.

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.

Mariani G, Fasolo A, De Benedictis E, Gianni L.

Nat Clin Pract Oncol. 2009 Feb;6(2):93-104. doi: 10.1038/ncponc1298. Review.

PMID:
19107109
16.

Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.

Mehra R, Burtness B.

Expert Opin Biol Ther. 2006 Sep;6(9):951-62. Review.

PMID:
16918262
17.

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

McKeage K, Lyseng-Williamson KA.

Pharmacoeconomics. 2008;26(8):699-719. Review.

PMID:
18620462
18.

Adjuvant trastuzumab for HER2-positive early breast cancer.

Palmieri FM, Myatt CV, Perez EA.

Clin J Oncol Nurs. 2010 Jun;14(3):326-36. doi: 10.1188/10.CJON.326-336. Review.

PMID:
20529794
19.

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.

Petrelli F, Barni S.

Med Oncol. 2011 Jun;28(2):401-8. doi: 10.1007/s12032-010-9460-0. Review.

PMID:
20195801
20.

HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M.

Breast Cancer Res Treat. 2008 May;109(2):209-29. Review.

PMID:
17636396
Items per page

Supplemental Content

Support Center